Introduction
============

Due to the improvement of living standards, greater work stress and reduced exercise intensity, abdominal obesity has been considered to represent a major worldwide public health problem in the 21st century, with an estimated age-adjusted prevalence of \~40.0% worldwide ([@b1-mmr-18-03-3314],[@b2-mmr-18-03-3314]). Abdominal obesity is associated with an increased risk of the development of numerous metabolic disorders, including diabetes, hypertension, dyslipidemia, hepatic steatosis and cardiovascular diseases, which may result in disability and sudden mortality ([@b3-mmr-18-03-3314],[@b4-mmr-18-03-3314]). Therefore, it is important to investigate the mechanisms underlying the initiation of abdominal obesity, in addition to associated metabolic alterations, in order to develop novel therapeutic strategies.

Abdominal obesity is characterized by the expansion of adipose tissue (AT) mass via enlargement of existing adipocytes (hypertrophy) and increased numbers of novel adipocytes (hyperplasia) ([@b5-mmr-18-03-3314]). Hypertrophy results in a limited blood supply to each adipocyte, which triggers tissue hypoxia and subsequent stimulation of numerous inflammatory responses, including proliferation and infiltration of M1 macrophages, in addition to the release of numerous pro-inflammatory cytokines, including interleukin (IL)-6, tumor necrosis factor (TNF)-α and IL-1β ([@b6-mmr-18-03-3314],[@b7-mmr-18-03-3314]). Such inflammatory cytokines may further contribute to adipogenesis ([@b8-mmr-18-03-3314]) and metabolic diseases ([@b9-mmr-18-03-3314],[@b10-mmr-18-03-3314]). Thus, targeted anti-inflammatory therapies have been suggested to be beneficial for the treatment of obesity and the prevention of associated metabolic disorders ([@b11-mmr-18-03-3314]--[@b13-mmr-18-03-3314]). However, current treatment strategies have been revealed to exhibit limited therapeutic benefits ([@b11-mmr-18-03-3314]--[@b13-mmr-18-03-3314]), suggesting that there are further mechanisms associated with AT inflammation in obesity.

Previous studies have demonstrated the regulatory roles of micro (mi)RNAs and small non-coding RNAs (19--22 nucleotides in length) in inflammatory obesity ([@b14-mmr-18-03-3314],[@b15-mmr-18-03-3314]). miRNAs function by inhibiting gene expression by binding to complementary sequences in the 3′untranslated region (UTR) of target genes, and may be present intracellularly or secreted extracellularly within nanoparticles, namely exosomes. Compared with endogenous miRNAs, adipocyte exosomes have attracted more attention in recent years due to their function as important mediators of intercellular communication and their ability to transfer phenotypic traits from mature and inflammatory adipocytes into surrounding cells of the same type (e.g. preadipocytes or non-inflammatory adipocytes) or other cells (e.g. liver or muscle cells) ([@b16-mmr-18-03-3314]), thus facilitating novel adipogenesis and the development of metabolic diseases. For example, exosomal miRNA (miR)-450a-5p in AT has been demonstrated to enhance adipogenesis via suppression of Wnt family member 1 inducible signaling pathway protein 2 expression by targeting its 3′UTR ([@b17-mmr-18-03-3314]). Furthermore, miR-155 has been revealed to be overexpressed in obese adipocyte-derived exosomes ([@b16-mmr-18-03-3314]). In addition, it has been demonstrated that miR-155 knockout animals are insulin sensitive and exhibit a greater glucose tolerance compared with control animals ([@b16-mmr-18-03-3314]). Furthermore, a previous study suggested that miR-155 interferes with insulin signaling and insulin-induced glucose uptake in adipocytes via suppression of suppressor of cytokine signaling 1 protein expression levels and subsequent suppression of signal transducer and activator of transcription 6 signaling, which promotes M1 macrophage polarization ([@b18-mmr-18-03-3314]). A previous study also uses miRNA arrays to investigate exosomal miRNA profiles in visceral adipose tissues (VAT) obtained from patients with obesity, and reveal that miR-23b and miR-4429 may be important in the development of obesity by affecting transforming growth factor (TGF)-β signaling pathways ([@b19-mmr-18-03-3314]). However, studies investigating exosomal miRNAs in adipocytes are rare, and, to the best of our knowledge, there have been no clinical studies investigating the use of exosomal miRNAs in adipocytes.

Abdominal ATs associated with complications arising from obesity include subcutaneous adipose tissue (SAT) and VAT ([@b20-mmr-18-03-3314]). Despite VAT having been previously studied, increasing studies have suggested that SAT accumulation may represent a potential predictor for insulin resistance and metabolic syndrome ([@b21-mmr-18-03-3314]--[@b23-mmr-18-03-3314]). Therefore, understanding of which exosomal miRNAs exert important roles in SAT and how these are performed may further the understanding of the pathogenesis associated with abdominal obesity. The aim of the present study was to analyze exosomal miRNA profiles in SAT obtained from patients with obesity and from lean patients, and to preliminarily determine associated functions via target prediction. Furthermore, the microarray data of exosomal miRNAs in VAT were further analyzed using different analytical methods (Student\'s t-tests vs. three-way analysis of covariance) and loose threshold values \[\|log fold change (FC)\|\>0.5 vs. FC≥\|1.2\| ([@b19-mmr-18-03-3314])\], which were subsequently compared with SAT to determine shared and specific exosomal miRNAs, which may reveal further potential targets for the treatment of patients with obesity and associated metabolic disorders.

Materials and methods
=====================

### Microarray data

miRNA microarray data were collected from the Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo>) under accession nos. GSE68885 and GSE50574 ([@b19-mmr-18-03-3314]), in which the exosomal miRNAs profiles from SAT and VAT obtained from seven patients with obesity and five lean patients (n=12) were investigated. Patients with obesity were recruited from adolescent bariatric surgery programs, and lean subjects were obtained from patients undergoing unrelated abdominal procedures in the Children\'s National Medical Center (Washington, DC, USA) ([@b19-mmr-18-03-3314]). None of the included patients had been administered any noteworthy medication prior to surgery. SAT was excised from the anterior abdominal wall incision site and VAT was excised from the omentum ([@b19-mmr-18-03-3314]).

mRNA microarray datasets were also obtained from the GEO database with the accession no. GSE29718 ([@b24-mmr-18-03-3314]), which analyzed the mRNA profiles from 15 SAT samples (seven patients with obesity and eight lean patients) and five VAT samples (three patients with obesity and two lean patients). All samples were collected from patients undergoing an elective procedure in the Garvan Institute of Medical Research (Darlinghurst, New South Wales, Australia) wherein abdominal fat could be obtained ([@b24-mmr-18-03-3314]).

### Data normalization and identification of differentially expressed (DE)-miRNAs and differentially expressed genes (DEGs)

The series matrix files of the aforementioned datasets and the annotated symbols were downloaded from the Affymetrix Multispecies miRNA-3 Array platform, GPL16384 ([@b19-mmr-18-03-3314]); or \[HuGene-1_0-st\] Affymetrix Human Gene 1.0 ST Array \[transcript (gene) version\] platform, GPL6244 ([@b24-mmr-18-03-3314]) (both Affymetrix; Thermo Fisher Scientific, Inc., Waltham, MA, USA; <http://www.ncbi.nlm.nih.gov/geo>). If numerous probes corresponded to the same gene, the mean value was considered to represent the expression value of this gene. Missing values of probes were imputed using the nearest neighbor averaging method in the impute package ([@b25-mmr-18-03-3314]) in R (v1.0; <http://bioconductor.org/packages/release/bioc/html/impute.html>) ([@b26-mmr-18-03-3314]) with default parameters. Subsequently, all expression values were logarithmically transformed (base 2) and quantile-normalized using the Bioconductor preprocessCore package (v1.28.0; <http://www.bioconductor.org/packages/release/bioc/html/preprocessCore.html>) ([@b27-mmr-18-03-3314]).

DE-miRNAs and DEGs between patients with obesity and lean patients were identified using the Linear Models for Microarray Data method (v2.16.4; <http://bioconductor.org/packages/release/bioc/html/limma.html>) ([@b28-mmr-18-03-3314]) using the Bioconductor R package. P-values were calculated using an unpaired Student\'s t-test. P\<0.05 and \|logFC\|\>0.5 were considered to indicate statistically significant differences regarding DE-miRNA and DEG analyses. In order to determine the intersection of target genes and DEGs, the threshold values of DEGs in SATs were set at P\<0.05 and \|logFC\|\>0.45. Heat maps of DE-miRNAs and DEGs were generated using the heatmap R package (v1.0.8; [cran.r-project.org/web/packages/pheatmap/index.html](cran.r-project.org/web/packages/pheatmap/index.html)) based on Euclidean clustering distances ([@b29-mmr-18-03-3314]). Furthermore, shared and specific SAT and VAT DE-miRNAs were analyzed using a Venn diagram (<http://bioinformatics.psb.ugent.be/webtools/Venn/>).

### Target gene prediction of DE-miRNAs

mRNA targets of DE-miRNAs were predicted using the miRWalk database (v2.0; <http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/>) ([@b30-mmr-18-03-3314]), which is a comprehensive archive providing a collection of predicted and experimentally verified miRNA-target interactions using 12 prediction programs \[DIANA-microT (v4.0), DIANA-microT-CDS (v5.0), miRanda-rel (v1.0), mirBridge (v1.0), miRDB (v4.0), miRmap (v1.0), miRNAMap (v1.0), PicTar (v2.0), PITA (v6.0), RNA22 (v2.0), RNAhybrid (v2.1) and Targetscan (v6.2)\]. The DE-miRNA-target interactions were visualized using Cytoscape software (v2.8; [www.cytoscape.org/](www.cytoscape.org/)) ([@b31-mmr-18-03-3314]).

### Functional enrichment analysis

In order to investigate the functions associated with the identified target genes at the functional level, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) online tool (v6.8; <http://david.abcc.ncifcrf.gov>) ([@b32-mmr-18-03-3314]). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Identification of exosomal DE-miRNAs between patients with obesity and lean patients

According to the threshold values of P\<0.05 and \|logFC\|\>0.5, 10 exosome-derived DE-miRNAs were identified in SATs between patients with obesity and lean patients, including nine downregulated DE-miRNAs (hsa-miR-1273d, hsa-miR-181d, hsa-miR-2861, hsa-miR-3156-5p, hsa-miR-32, hsa-miR-4517, hsa-miR-4728-5p, hsa-miR-4758-5p and hsa-miR-938) and one upregulated DE-miRNA (hsa-miR-4460; [Table I](#tI-mmr-18-03-3314){ref-type="table"}); whereas, 58 exosomal DE-miRNAs were identified in VATs, including 44 downregulated DE-miRNAs (e.g. hsa-miR-4517, hsa-miR-532-3p and hsa-miR-582-5p) and 14 upregulated DE-miRNAs (e.g. hsa-miR-4487; [Table I](#tI-mmr-18-03-3314){ref-type="table"}). Heatmaps generated by the pheatmap package in R suggested that the identified DE-miRNAs in SAT ([Fig. 1A](#f1-mmr-18-03-3314){ref-type="fig"}) and VAT ([Fig. 1B](#f1-mmr-18-03-3314){ref-type="fig"}) were distinguishable between patients with obesity and lean patients. Venn diagram analysis revealed that there was only one shared exosomal DE-miRNA (hsa-miR-4517) in SAT and VAT; whereas, the other nine DE-mRNAs in SAT and 57 DE-miRNAs in VAT were tissue-specific ([Fig. 1C](#f1-mmr-18-03-3314){ref-type="fig"}).

### Target genes for DE-miRNAs

To investigate the potential involvement of the aforementioned DE-miRNAs in the pathogenesis of diseases associated with obesity, 1,622 and 3,384 potential targets were respectively identified to be associated with the 10 and 58 DE-miRNAs in SAT and VAT, respectively, using the miRWalk2 database. Among them, the shared hsa-miR-4517 between SAT and VAT was revealed to regulate 101 target genes, including ras homolog family member A (RhoA; [Fig. 2](#f2-mmr-18-03-3314){ref-type="fig"}).

To investigate whether the expression levels of DE-miRNA target genes were differential in patients with obesity and lean patients, mRNA expression profiles in SAT and VAT obtained from patients with obesity and lean patients were also determined. The results revealed that 168 (including 61 upregulated and 107 downregulated) and 487 (including 143 upregulated and 344 downregulated) DEGs were identified in SAT and VAT when comparing patients with obesity to lean patients, respectively ([Table II](#tII-mmr-18-03-3314){ref-type="table"}). Following overlapping with the target genes of 10 DE-miRNAs, only one DEG (CD86) with converse expression to the miRNAs remained for SAT. This upregulated DEG may be regulated by downregulated hsa-miR-3156-5p ([Fig. 3A](#f3-mmr-18-03-3314){ref-type="fig"}). Regarding the VAT samples, 25 DEGs (including 14 upregulated and 11 downregulated) were revealed to be overlapping with the target genes of 58 DE-miRNAs ([Table II](#tII-mmr-18-03-3314){ref-type="table"}; [Fig. 3B](#f3-mmr-18-03-3314){ref-type="fig"}). Upregulated genes in patients with obesity were regulated by downregulated hsa-miR-1253, hsa-miR-1286, hsa-miR-140-3p, hsa-miR-3160-3p, hsa-miR-4252, hsa-miR-4269, hsa-miR-4305, hsa-miR-4635, hsa-miR-4770, hsa-miR-5095, hsa-miR-532-3p, hsa-miR-566 and hsa-miR-582-5p; whereas the downregulated genes in patients with obesity were regulated by upregulated hsa-miR-1825, hsa-miR-3940-5p, hsa-miR-4487, hsa-miR-4717-3p, hsa-miR-548ac, hsa-miR-548z and hsa-miR-548an ([Fig. 3B](#f3-mmr-18-03-3314){ref-type="fig"}).

### Functional enrichment analysis

Target genes of DE-miRNAs were subjected to functional enrichment analysis using DAVID software. As a result, the GO enrichment results demonstrated that the target genes of DE-miRNAs in SAT were involved in 'positive regulation of transcription, DNA-templated' (e.g. CD86) and 'toll-like receptor 3 signaling pathway' (e.g. CD86; [Table III](#tIII-mmr-18-03-3314){ref-type="table"}). A total of 28 KEGG pathways were enriched for the target genes of DE-miRNAs in exosomes, including 'endocytosis', 'neurotrophin signaling pathway', 'TGF-β signaling pathway' (e.g. RhoA) and 'thyroid hormone signaling pathway' (e.g. mediator complex subunit 13; [Table IV](#tIV-mmr-18-03-3314){ref-type="table"}).

Furthermore, the 25 overlapping DEGs regulated by DE-miRNAs in VAT were also subjected to functional enrichment analysis using DAVID software. The results revealed that 'positive regulation of transcription from RNA polymerase II promoter' \[Fos-like antigen 2 (FOSL2)\], 'positive chemotaxis' \[fibroblast growth factor 2 (FGF2)\] and 'ATP metabolic process' \[adenosine monophosphate deaminase 3 (AMPD3)\] were enriched in VAT ([Table III](#tIII-mmr-18-03-3314){ref-type="table"}).

Discussion
==========

To the best of our knowledge, the present study is the first to have investigated the exosomal miRNA profiles in SAT obtained from patients with obesity and lean patients, the results of which identified 10 DE-miRNAs, including nine downregulated DE-miRNAs (hsa-miR-1273d, hsa-miR-181d, hsa-miR-2861, hsa-miR-3156-5p, hsa-miR-32, hsa-miR-4517, hsa-miR-4728-5p, hsa-miR-4758-5p and hsa-miR-938) and one upregulated DE-miRNA (hsa-miR-4460). The majority of DE-miRNAs identified in SAT were not identified in VAT, further revealing the difference between visceral and subcutaneous adipocytes in abdominal obesity, which was consistent with previous studies ([@b33-mmr-18-03-3314],[@b34-mmr-18-03-3314]). Only one exosomal miRNA, hsa-miR-4517, was demonstrated to be shared between SAT and VAT. This miRNA was also identified by Ferrante *et al* ([@b19-mmr-18-03-3314]), thus demonstrating its importance in obesity. Notably, hsa-miR-4517 was predicted to inhibit the expression of RhoA in the present study. Rho-kinase functions as an important regulator of inflammation, proliferation and fibrosis via activation of the mitogen-activated protein kinase (MAPK)/extracellular signa-regulated kinase, nuclear factor (NF)-κB subunit and p38MAPK pathways ([@b35-mmr-18-03-3314]--[@b37-mmr-18-03-3314]). Thus, RhoA has been previously reported to be activated in inflammatory obesity and metabolic syndrome. The use of RhoA inhibitors may ameliorate obesity and disorders associated with obesity ([@b35-mmr-18-03-3314]--[@b37-mmr-18-03-3314]). In the present study, it was hypothesized that hsa-miR-4517 may function as an inhibitor of RhoA and that exosomes may be responsible for the transfer of hsa-miR-4517 from mature adipocytes to preadipocytes or distant liver tissue cells, where hsa-miR-4517 may subsequently inhibit RhoA to maintain lean body mass and prevent distant injury; however, downregulation of exosomal hsa-miR-4517 has been previously demonstrated to lead to the development of obesity and liver diseases ([@b16-mmr-18-03-3314],[@b17-mmr-18-03-3314]). The present hypothesis has been indirectly demonstrated by a recent study, which revealed that miR-4517 mimics ameliorated hepatic steatosis induced by free fatty acids ([@b38-mmr-18-03-3314]). The results of the present study demonstrated that RhoA mRNA expression levels were not significantly different between obese and lean patients in SAT and VAT, which may be attributable to the use of small sample sizes. Therefore, further investigation is required to confirm the aforementioned hypothesized mechanisms regarding the association between exosomal miR-4517 and obesity.

Among the other nine SAT-specific exosomal DE-miRNAs, hsa-miR-3156-5p was demonstrated to negatively regulate CD86 and subsequently to be involved in the inflammatory toll-like receptor (TLR) 3 signaling pathway. Thus, aberrant expression of hsa-miR-3156-5p may represent an important factor associated with obesity. Recent studies have predominantly focused on the association between hsa-miR-3156-5p and cancer ([@b39-mmr-18-03-3314],[@b40-mmr-18-03-3314]), which has a similar inflammatory mechanism to obesity. However, the association between CD86 and obesity has been extensively studied. For example, Sindhu *et al* ([@b41-mmr-18-03-3314]) revealed that CD86 protein expression was significantly enhanced in adipose tissue samples obtained from patients with obesity. Furthermore, CD86 has been demonstrated to be positively correlated with the levels of pro-inflammatory cytokines in adipose tissues, including IL-18, IL-18R and TLR8 ([@b42-mmr-18-03-3314],[@b43-mmr-18-03-3314]). Vitamin D supplementation, which decreases the expression of CD86 in the spleen, has been proposed as a treatment option to alleviate high-fat diet-induced obesity ([@b44-mmr-18-03-3314]). Therefore, it was hypothesized that the downregulation of exosomal hsa-miR-3156-5p may result in the development of obesity and liver diseases due to its inability to inhibit inflammation. In the present study, hsa-miR-4460 was the only miRNA identified to be upregulated in the exosomes of SAT in patients with obesity compared with lean patients. Overexpression of hsa-miR-4460 was predicted to inhibit the expression of mediator complex subunit 13 (MED13), which was also revealed to be downregulated in SAT obtained from patients with obesity. A previous study demonstrated that cardiac overexpression of MED13 confers a lean phenotype on mice via increased lipid uptake, β-oxidation and mitochondrial content in white adipose tissues and liver tissues ([@b45-mmr-18-03-3314]). Thus, downregulation of MED13 by hsa-miR-4460 may contribute to the development of obesity via the suppression of metabolism. Treatment with exosomes possessing anti-miR-4460 may represent a therapeutic strategy for the treatment of patients suffering from obesity and associated complications.

As opposed to the results generated by SAT analysis, further investigation revealed that exosomal hsa-miR-582-5p, hsa-miR-566 and miR-548 may be important in VAT-associated diseases by respectively upregulating FGF2, FOSL2 and AMPD3, all of which are associated with inflammation. The results of the present study were in agreement with numerous previous studies. For example, Shao *et al* ([@b46-mmr-18-03-3314]) demonstrated that ectopic expression of FGF2 in mouse joints enhanced the levels of IL-17-induced inflammatory cytokines and the production of chemokines in the tissue, which resulted in exacerbated symptoms of autoimmune arthritis. Drosos *et al* ([@b47-mmr-18-03-3314]) revealed that the upregulation of hypoxia-inducible factor-1α and FOSL2 in perivascular adipose tissues may enhance leptin gene transcription, which further induces vascularization and inflammation, ultimately contributing to increased atherosclerotic plaque burden in the coronary arteries. In addition, Li *et al* ([@b48-mmr-18-03-3314]) demonstrated that a genetic deficiency of AMPD3 resulted in markedly enhanced infiltration of neutrophils in the lungs, which further increased reperfusion-induced lung injury. Thus, modification of exosomes via transfection with hsa-miR-582-5p, hsa-miR-566 or anti-miR-548 may represent novel therapeutic approaches for the treatment of patients with obesity and associated diseases.

There were a number of limitations to the present study. Firstly, only exosomal miRNAs and mRNA expression profile data were downloaded from the GEO database. Future studies using patient data are required to confirm the results of the present study. Secondly, the sample size was small, which may have resulted in a number of unexpected statistical deviations regarding the analyses performed to investigate the roles of miRNAs and mRNAs. Furthermore, despite the results of the present study having preliminarily speculated negative associations between numerous miRNAs and their target genes, *in vitro* and *in vivo* experiments are required to confirm these results ([@b16-mmr-18-03-3314]--[@b19-mmr-18-03-3314]). In addition, the results of the present study suggested that exosomal miRNAs in mature SAT and VAT may affect peripheral or distant liver tissue cells, which subsequently leads to the development of obesity and obesity-associated disorders; however, this proposed mechanism requires further experimental validation ([@b17-mmr-18-03-3314]).

The present study preliminarily investigated the profiles of exosomal miRNAs in SAT and VAT obtained from patients with obesity, in addition to the mechanisms underlying obesity. The results of the present study revealed that hsa-miR-4517 was a shared downregulated exosomal miRNA between SAT and VAT, which upregulated its target gene, RhoA. The results demonstrated that downregulated hsa-miR-3156-5p and upregulated hsa-miR-4460 may represent important and specific exosomal miRNAs in SAT via regulation of CD86 and MED13, respectively; whereas, hsa-miR-582-5p, hsa-miR-566 and miR-548 were revealed to be important in VAT via regulation of FGF2, FOSL2 and AMPD3, respectively. All of the aforementioned target genes were revealed to be associated with inflammation, and thus such target genes and their respective miRNAs may represent novel therapeutic targets for the treatment of obesity and associated metabolic alterations.
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![Differentially expressed exosomal miRNAs were identified between the patients with obesity and the lean patients. (A) Heat map of DE-miRNAs in the GSE68885 dataset, which included subcutaneous adipose tissue samples obtained from patients with obesity and lean patients (red indicates high expression, green indicates low expression). (B) Heat map of DE-miRNAs in the GSE50574 dataset, which included visceral adipose tissue samples obtained from patients with obesity and lean patients (red indicates high expression, green indicates low expression). (C) The Venn diagram revealed the intersection of DE-miRNAs between subcutaneous and visceral adipose tissues. DE, differentially expressed; miRNA, microRNA.](MMR-18-03-3314-g00){#f1-mmr-18-03-3314}

![Regulatory network of shared exosomal hsa-microRNA-4517 between subcutaneous and visceral adipose tissues and associated target genes.](MMR-18-03-3314-g01){#f2-mmr-18-03-3314}

![Important genes associated with DE-miRNAs. (A) The regulatory association between the important DE-miRNA and its associated target gene in subcutaneous adipose tissues. (B) Regulatory associations between important DE-miRNAs and associated target genes in visceral adipose tissues. Diamonds represent miRNAs (yellow represents downregulated miRNAs; purple represents upregulated miRNAs); ovals represent DE target genes (red represents upregulated DE target genes; green represents downregulated DE target genes). DE, differentially expressed; miRNA, microRNA.](MMR-18-03-3314-g02){#f3-mmr-18-03-3314}

###### 

Differentially expressed microRNAs of subcutaneous and visceral adipose tissues between obese and lean subjects.

  A, Subcutaneous adipose tissues               
  --------------------------------- ----------- -------------
  hsa-miR-1273d                     −0.597      0.032
  hsa-miR-181d                      −0.662      0.023
  hsa-miR-2861                      −0.732      0.032
  hsa-miR-3156-5p                   −0.593      0.011
  hsa-miR-32                        −0.593      0.048
  hsa-miR-4517                      −0.696      0.039
  hsa-miR-4728-5p                   −1.156      0.038
  hsa-miR-4758-5p                   −0.636      0.029
  hsa-miR-938                       −0.560      0.028
  hsa-miR-4460                      0.556       0.018
                                                
  **B, Visceral adipose tissues**               
                                                
  **miRNA**                         **logFC**   **P-value**
                                                
  hsa-miR-4733-5p                   −0.514      0.022
  hsa-miR-1286                      −0.514      0.019
  hsa-miR-4319                      −0.528      0.007
  hsa-miR-3605-5p                   −0.531      0.036
  hsa-miR-4676-3p                   −0.536      0.043
  hsa-miR-192                       −0.572      0.010
  hsa-miR-4770                      −0.644      0.023
  hsa-miR-4713-5p                   −0.662      0.037
  hsa-miR-3160-3p                   −0.689      0.038
  hsa-miR-215                       −0.723      0.004
  hsa-miR-582-5p                    −0.734      0.012
  hsa-miR-3938                      −0.741      0.024
  hsa-miR-133a                      −0.750      0.032
  hsa-miR-532-3p                    −0.754      0.050
  hsa-miR-4798-3p                   −0.761      0.034
  hsa-miR-3690                      −0.769      0.046
  hsa-miR-597                       −0.800      0.003
  hsa-miR-4305                      −0.865      0.033
  hsa-miR-2964a-5p                  −0.900      0.009
  hsa-miR-379-star                  −0.909      0.020
  hsa-miR-566                       −0.911      0.036
  hsa-miR-3940-3p                   −0.922      0.020
  hsa-miR-3620                      −0.942      0.025
  hsa-miR-196b-star                 −0.974      0.032
  hsa-miR-3975                      −0.986      0.023
  hsa-miR-1253                      −0.987      0.010
  hsa-miR-2681-star                 −1.048      0.011
  hsa-miR-182                       −1.048      0.003
  hsa-miR-4517                      −1.048      0.008
  hsa-miR-4753-5p                   −1.061      0.009
  hsa-miR-140-3p                    −1.097      0.047
  hsa-miR-629-star                  −1.110      0.017
  hsa-miR-3681-star                 −1.110      0.005
  hsa-miR-4735-5p                   −1.114      0.022
  hsa-miR-148b                      −1.131      0.008
  hsa-miR-4269                      −1.147      0.019
  hsa-miR-4252                      −1.165      0.025
  hsa-miR-3161                      −1.172      0.008
  hsa-miR-654-3p                    −1.192      0.002
  hsa-miR-758                       −1.207      \<0.001
  hsa-miR-4635                      −1.258      0.013
  hsa-miR-5095                      −1.360      0.023
  hsa-miR-4782-5p                   −1.443      0.041
  hsa-miR-4474-5p                   −1.513      0.002
  hsa-miR-548an                     1.014       0.006
  hsa-miR-4717-3p                   1.004       0.028
  hsa-miR-4487                      1.004       0.001
  hsa-miR-3613-5p                   0.995       0.033
  hsa-miR-1825                      0.942       0.042
  hsa-miR-191-star                  0.848       0.041
  hsa-miR-4800-3p                   0.815       0.022
  hsa-miR-378h                      0.812       0.037
  hsa-miR-425-star                  0.802       0.037
  hsa-miR-4787-5p                   0.771       0.014
  hsa-miR-3940-5p                   0.768       0.033
  hsa-miR-548ac                     0.695       0.040
  hsa-miR-548ae                     0.664       0.017
  hsa-miR-548z                      0.624       0.048

FC, fold change; miR/miRNA, microRNA.

###### 

Differentially expressed genes of subcutaneous and visceral adipose tissues between obese and lean subjects.

  A, Subcutaneous adipose tissues               
  --------------------------------- ----------- -------------
  IFNA10                            0.644       0.001
  TIGAR                             0.790       \<0.001
  FAM72A                            0.501       0.002
  FCGR2A                            0.640       0.003
  TM4SF19-TCTEX1D2                  1.195       0.003
  CLEC12A                           0.747       0.004
  NCEH1                             0.569       0.005
  AIF1                              0.519       0.008
  CD86                              0.495       0.022
  FAM105A                           0.406       0.027
  HP                                0.960       0.008
  EPDR1                             0.530       0.008
  NIPSNAP3B                         −0.734      0.001
  ABHD5                             −0.833      0.002
  MYOCD                             −0.554      0.002
  PFKFB3                            −0.620      0.004
  AGTR1                             −0.700      0.005
  ZBTB16                            −0.894      0.006
  CYP4B1                            −0.815      0.007
  TSC22D3                           −0.543      0.007
  CALCRL                            −0.674      0.008
  ACACB                             −0.532      0.008
  SLC27A2                           −1.470      0.010
  RDH10                             −0.680      0.010
                                                
  **B, Visceral adipose tissues**               
                                                
  **Gene**                          **logFC**   **P-value**
                                                
  SLFN12L                           1.039       0.003
  FOSL2                             0.835       0.005
  SRPX2                             1.216       0.008
  DHCR24                            1.411       0.012
  LIPC                              0.526       0.013
  PER1                              0.803       0.017
  SLC10A6                           0.566       0.018
  FPR2                              1.020       0.025
  FSTL3                             0.540       0.025
  C1RL                              0.518       0.026
  FGF2                              0.575       0.027
  DNAJA1                            0.576       0.031
  MSMO1                             0.705       0.039
  SLC25A25                          0.966       0.048
  MYOCD                             −0.845      0.004
  AMPD3                             −0.663      0.010
  PDE5A                             −0.544      0.012
  VAV3                              −0.723      0.021
  P2RY10                            −1.259      0.022
  MYBL1                             −0.611      0.022
  APIP                              −0.508      0.023
  HMGB2                             −0.573      0.024
  HIST1H2BH                         −0.544      0.038
  ADAM28                            −1.283      0.043

###### 

Gene Ontology biological process term enrichment results for target genes of differentially expressed microRNAs in subcutaneous and visceral adipose tissues between obese and lean subjects.

  A, SAT                                                                                                                       
  ------------ ----------------------------------------------------------------------------------------------- --------- ----- ----------------------------------------------------------------------------
  GO:0006351   Transcription, DNA-templated                                                                    \<0.001   236   ITGB3BP, PRR13, ATP1B4, XRCC6, ZNF781, ZNF250, ZNF253, CRY2, MED28, MED29
  GO:0006355   Regulation of transcription, DNA-templated                                                      \<0.001   184   RALY, ITGB3BP, ZNF584, THRA, PRR13, ATP1B4, ZNF781, CNOT2, ZNF250, ZNF253
  GO:0050821   Protein stabilization                                                                           \<0.001   27    HSP90AB1, ATP1B3, SOX4, HSPA1B, CALR, PTEN, SUMO1, APOA1, MORC3, CREBL2
  GO:0071456   Cellular response to hypoxia                                                                    \<0.001   20    ICAM1, ACAA2, CPEB2, TP53, PMAIP1, PTEN, KCNMB1, KCNK3, SUV39H2, SLC29A1
  GO:0043161   Proteasome-mediated ubiquitin-dependent protein catabolic process                               \<0.001   33    TRIM13, RNF187, RLIM, CD2AP, AMER1, UBXN2A, C18ORF25, UBXN2B, BTBD2, PSMD3
  GO:0016567   Protein ubiquitination                                                                          \<0.001   50    BACH2, MYLIP, RLIM, ZNRF3, KLHL5, G2E3, ZYG11A, KLHL26, RNF103, KLHL21
  GO:0006977   DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest   \<0.001   15    RBL2, TP53, CNOT2, SOX4, AURKA, ATM, CNOT4, CCNB1, CDKN1A, EP300
  GO:0097193   Intrinsic apoptotic signaling pathway                                                           \<0.001   10    CDKN1A, CUL5, HRAS, DDX3X, SGPP1, BBC3, CYCS, TP53, APAF1, PMAIP1
  GO:0051301   Cell division                                                                                   \<0.001   48    ITGB3BP, HAUS3, CLTA, SEPT2, MPLKIP, TSG101, BORA, ARF6, AURKA, NR3C1
  GO:0045893   Positive regulation of transcription, DNA-templated                                             \<0.001   65    E2F3, PTGES2, RSF1, FGF7, GPBP1, XRCC6, RNF187, ZKSCAN3, ZXDA, CD86
  GO:0034138   Toll-like receptor 3 signaling pathway                                                          0.024     4     HAVCR2, CD86, TLR3, COLEC12
                                                                                                                               
  **B, VAT**                                                                                                                   
                                                                                                                               
  GO:0045944   Positive regulation of transcription from RNA polymerase II promoter                            0.001     7     HMGB2, FOSL2, MYOCD, FSTL3, PER1, MYBL1, FGF2
  GO:0007283   Spermatogenesis                                                                                 0.013     4     ADAM28, HMGB2, DNAJA1, FSTL3
  GO:0045893   Positive regulation of transcription, DNA-templated                                             0.029     4     HMGB2, MYOCD, MYBL1, FGF2
  GO:0043388   Positive regulation of DNA binding                                                              0.036     2     HMGB2, MYOCD
  GO:0043552   Positive regulation of phosphatidylinositol 3-kinase activity                                   0.040     2     VAV3, FGF2
  GO:0046034   ATP metabolic process                                                                           0.041     2     SLC25A25, AMPD3
  GO:0050918   Positive chemotaxis                                                                             0.045     2     HMGB2, FGF2
  GO:0006695   Cholesterol biosynthetic process                                                                0.049     2     MSMO1, DHCR24

The top 10 genes are presented for each GO term if the overall count of enriched genes was \>10. GO, Gene Ontology; SAT, subcutaneous adipose tissues; VAT, visceral adipose tissues.

###### 

KEGG pathways for target genes of differentially expressed microRNAs in subcutaneous and visceral adipose tissues between obese and lean subjects.

  A, SAT                                                                               
  ------------ --------------------------------------------- ------------- ----------- ----------------------------------------------------------------------------
  hsa04144     Endocytosis                                   \<0.001       46          RAB7A, CLTA, CAV1, PARD3, HRAS, LDLR, TSG101, KIAA0196, ASAP1, RhoA
  hsa04115     p53 signaling pathway                         \<0.001       18          CYCS, TP53, IGF1, PMAIP1, CCNG1, SESN2, PTEN, ATM, SESN3, CCNB1
  hsa04722     Neurotrophin signaling pathway                \<0.001       22          HRAS, TP53, FASLG, PRKCD, IRAK3, NRAS, MAP3K5, RPS6KA3, CRKL, RHOA
  hsa04151     PI3K-Akt signaling pathway                    0.001         45          HSP90AB1, HRAS, FGF7, PHLPP2, MCL1, OSMR, STK11, ITGA11, FASLG, BCL2L11
  hsa04919     Thyroid hormone signaling pathway             0.004         19          HRAS, KAT2B, THRA, ATP1B3, ATP1B4, CREBBP, TP53, ITGB3, MED13, NRAS
  hsa04068     FoxO signaling pathway                        0.011         20          HRAS, RBL2, SGK3, STK11, TGFBR1, CREBBP, IGF1, FASLG, STK4, BCL2L11
  hsa04066     HIF-1 signaling pathway                       0.025         15          CREBBP, MKNK2, IGF1, CDKN1A, EIF4EBP1, EP300, CDKN1B, TFRC, BCL2, PLCG2
  hsa04141     Protein processing in endoplasmic reticulum   0.031         22          HSP90AB1, MAN1A2, UBE2G1, PDIA6, DNAJB12, HSPA1B, CALR, LMAN1, EDEM1, CANX
  hsa04152     AMPK signaling pathway                        0.036         17          SREBF1, STK11, HMGCR, SCD, IGF1, CREB5, ADIPOQ, CPT1A, EIF4EBP1, TSC1
  hsa04350     TGF-β signaling pathway                       0.037         13          SMAD9, SMAD7, TGFBR1, SMAD6, CREBBP, BMPR2, EP300, PPP2CA, RHOA, ID4
  hsa04010     MAPK signaling pathway                        0.037         30          HRAS, FGF7, MAPKAPK5, DUSP10, CACNB1, MKNK2, FASLG, HSPA1B, MAP3K5, MAP3K3
  hsa04145     Phagosome                                     0.039         20          MBL2, RAB7A, DYNC1LI2, RAB7B, C3, TUBB2A, HLA-A, COLEC12, ITGB3, ATP6V1G1
                                                                                       
  **B, VAT**                                                                           
                                                                                       
               **KEGG pathways**                             **P-value**   **Count**   **Genes**
                                                                                       
  hsa00100     Steroid biosynthesis                          0.040           2         MSMO1, DHCR24

The top 10 genes are presented for each KEGG pathway if the overall count of enriched genes was \>10. KEGG, Kyoto Encyclopedia of Genes and Genomes; SAT, subcutaneous adipose tissues; VAT, visceral adipose tissues.
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